Adding creatine while using finasteride and minoxidil caused skin irritation and hair thinning. Creatine may affect DHT levels, leading to these issues.
Dutasteride may cause chronic infertility by reducing semen volume and motility, with concerns about irreversible prostate fibrosis. Users consider switching to finasteride or using treatments like minoxidil and microneedling, weighing hair preservation against fertility.
Finasteride's long-term risks are often exaggerated; studies showing negative effects typically involve high doses or animal subjects. For those taking 1mg daily for hair loss, there is no significant evidence of severe side effects.
A user is asking about increasing their dutasteride dosage from 0.5mg to up to 2.5mg and whether it improves hair loss treatment. They are seeking experiences from others who have tried higher doses.
Microneedling is effective for hair growth, especially when combined with finasteride and minoxidil, but concerns exist about potential long-term skin damage. Users report increased collagen and elastin deposition, but the long-term effects on the scalp remain uncertain.
The user experienced a panic attack after adding 5% topical minoxidil to their routine, which already included oral finasteride and minoxidil, and microneedling. They are seeking advice on whether microneedling increased absorption and if the anxiety attacks will subside.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.
Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.
The user experiences severe anxiety and physical symptoms after taking finasteride and is seeking alternative hair loss treatments since dutasteride is unavailable. They suspect an allergic reaction to finasteride and have stopped using it.
A user started taking 0.625mg oral minoxidil daily for hair loss, increased the dose to 1.25mg, and experienced a significant shed, losing 70% of scalp density. They cannot tolerate finasteride due to side effects but are hopeful for hair regrowth despite the shedding.
N-Acetyl-Cysteine (NAC) is being explored for treating hair loss, but users report mixed results. Some also mention using Quercetin and Resveratrol without significant hair improvement.
Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.
Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
The user experienced severe scalp issues and hair loss after using ketoconazole shampoo, which worsened despite various treatments. They seek advice on restoring scalp health, suspecting an allergic reaction or imbalance caused by the shampoo.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
A user switched from Anageninc to Aesthetic Cosmetics for RU58841 and experienced increased shedding, questioning the product's authenticity. They seek advice on reliable sources for RU58841 in Australia.
The conversation is about a user experiencing hair shedding after starting oral minoxidil at 1.5mg for hair loss. Shedding is considered normal and may indicate the treatment is working, but it may take months to see full results; increasing the dose to 2.5mg should be carefully considered.
A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.
A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
A 32-year-old male experienced erectile dysfunction and decreased libido after using oral dutasteride and minoxidil for hair loss. He is considering switching to topical alternatives like Xyon dutasteride or RU58841 to reduce side effects.
A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
The user experienced initial hair improvement with finasteride but noticed worsening hair loss after switching to dutasteride. They are considering returning to finasteride due to persistent hair shedding and scalp itch.
The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.